Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV

Exclusion Criteria

• •1. History of CNS disease, such as brain metastases or epilepsy;
• •2. Use of other antipsychotic drugs (such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone, or such treatment is under scheduling during the study) within 30 days before enrollment; long-term use of phenothiazine as an antipsychotic agent;
• •3. Concurrent use of pharyngeal or abdominal radiotherapy;
• •4. Concurrent use of quinolone antibiotics;
• •5. Chronic alcoholism;
• •6. Known hypersensitivity to olanzapine;
• •7. Know arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within 6 months;
• •8. Known uncontrolled diabetes mellitus;
• •9. Vomiting or retching 24 hours before chemotherapy;
• •10. Use of anti-emesis drugs 48 hours before chemotherapy;
• •11. Concurrent use of amifostine;
• •12. Concurrent use of corticosteroids and the only anti-allergic choice is corticosteroids